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Abstract
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder with defining clinical features that include kinetic tremor, gait ataxia, and
parkinsonism, with associated features spanning medical, cognitive, and psychiatric clinical domains. The emerging model for the pathogenesis of FXTAS is that of
RNA toxicity as a consequence of the sequestration of RNA binding proteins by the expanded CGG-repeat element within the FMR1 message, thus compromising
the normal functions of those proteins. A principal challenge at this point is to determine precisely which proteins are involved in FXTAS pathogenesis and how to
prevent or reverse this process. A second challenge is to determine why there is incomplete penetrance of FXTAS among premutation carriers with identical CGG-
repeat lengths, and what the protective factors are in some carriers. Finally, the discovery in premutation mice of early neurodevelopmental abnormalities, some
occurring even during late embryogenesis, raises the question of whether FXTAS is the end-stage of a life-long process of neuronal dysregulation. If an extended
pre-clinical phase precedes the development of FXTAS, there is great potential for therapeutic intervention, years or even decades before its clinical features are
manifest.
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Introduction
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late
adult-onset neurodegenerative disorder that affects, with age- and
gender-specific penetrance, carriers of premutation alleles (55–200
CGG repeats) of the fragile X mental retardation 1 (FMR1) gene.
Defining clinical features of FXTAS include progressive kinetic
tremor; gait ataxia; and parkinsonism with associated, variable features
including cognitive impairment and executive dysfunction, peripheral
neuropathy, and dysautonomia. At the time of its discovery and initial
report,1 premutation carriers were generally regarded as asympto-
matic, with the features noted above ascribed to various other
conditions,2 or to ‘‘normal aging’’. The significance of the premutation
allele was thought to be primarily its propensity to expand, upon
maternal transmission, to a full mutation allele (.200 CGG repeats) in
the child.
Two critical observations have helped to define FXTAS as a novel,
premutation-associated disorder. Firstly, it was found that premutation
alleles of the FMR1 gene are transcriptionally up-regulated (Figure 1),
with some individuals producing more than eight times the normal
levels of FMR1 mRNA.3,4 This observation both established that there
is biochemical dysregulation (not just genetic instability) in premuta-
tion carriers—thus providing a context for clinical involvement—and
gave rise to the current model for FXTAS pathogenesis, namely, RNA
toxic gain-of-function of the expanded CGG-repeat mRNA.5,6
Secondly, because cases of FXTAS are largely limited to the
premutation range (FMRP levels at or near normal levels), and are
generally not found among those with full mutation alleles (FMRP
substantially diminished), the mechanisms of FXTAS and the
neurodevelopmental disorder, fragile X syndrome, must be entirely
distinct—one involving elevated mRNA and the other involving a
protein deficit.7 A related issue is that additional neurological and
medical signs that may have been regarded as unrelated to the
premutation (e.g., peripheral neuropathy, hypertension, autonomic
dysfunction) can be established as associated (or non-associated)
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through their linkage to the premutation-expanded allele; this finding
is particularly evident with the recent observation of medical problems
experienced by female carriers with FXTAS.8,9
However, the issues of RNA toxicity and premutation-association
also raise significant challenges. In the first instance, how does the
FMR1 mRNA cause toxicity and disease, and why does it not occur in
all premutation carriers? In the second instance, how do we determine
whether a given clinical feature is associated with, or prodromal to,
FXTAS, as opposed to its more general association with the
premutation, wherein it would have little predictive value for the
eventual onset of FXTAS? Successful resolution of these questions is
critically important to the development of accurate diagnoses and
treatment for the spectrum of premutation-associated disorders,
including not only FXTAS, but also fragile X-associated primary
ovarian insufficiency (FXPOI) and neurodevelopmental involvement
(attention deficit hyperactivity disorder [ADHD]; autism and autism
spectrum disorders [ASD]; seizures and intellectual disability [ID]10).
Indeed, these questions have much broader relevance to neurodegen-
erative disorders, since co-morbid features may reflect differing
pathogenic mechanisms. This issue is difficult enough for principally
monogenic disorders such as FXTAS, but is compounded for the more
common, sporadic disorders, such as Parkinson’s disease (PD) and
Alzheimer’s disease (AD).
Pathogenesis of FXTAS
As noted above, the fundamentally distinct nature of FMR1
expression in the premutation range (high mRNA, relatively preserved
FMRP levels), and the full mutation range (reduced/absent mRNA,
FMRP), led to the idea of an RNA-mediated pathogenesis of FXTAS,
based on the ‘‘RNA toxicity’’ model for myotonic dystrophy (DM).11,12
For the latter disorder, one or more proteins, including muscleblind-
like 1(MBNL1), is bound excessively (sequestered) by an expanded,
non-coding C(C)UG repeat element. For MBNL1, specific domains of
clinical involvement, e.g., myotonia and insulin resistance, arise from
the altered splicing of specific mRNAs due to functional insufficiency
of the sequestered protein. FXTAS pathogenesis is believed to operate
through a similar mechanism, whereby the expanded CGG-repeat
element in the 59 non-coding portion of FMR1 mRNA sequesters
protein(s) that affect diverse pathways, leading to clinical involvement
(Figure 1). For FXTAS, the fundamental challenge at this point is two-
fold; namely, to establish that the FMR1 mRNA is necessary and
sufficient to produce all features of the neurodegenerative disorder
and, predicated on the correctness of the model, to identify the specific
proteins involved in mediating the RNA-triggered pathogenesis.
At present, several proteins have been identified that both interact
with the CGG repeat and are potential mediators of downstream
cellular dysregulation. Among these proteins are Sam68,13 a splicing
modulator whose absence in the mouse leads to motor dysfunc-
tion;14,15 Pur a,16,17 an RNA-binding protein whose targeted
disruption in mouse leads to tremor and gait disturbances, and early
loss of viability;18 and hnRNP A2,17,19 a multifunctional hetero-
geneous nuclear RNA binding protein thought to be involved with
mRNA metabolism and transport. For Sam68, there is evidence of
functional impairment in the brains of individuals with FXTAS, with
disease-specific alterations in splicing of ATP11B and SMN2 mRNAs.
There is also recovery of control isoform ratios in cultured cells
harboring expanded CGG-repeat alleles upon over-expression of
exogenous Sam68 protein.13 Similarly, overexpression of Pur a protein
in a CGG-repeat Drosophila model reverses a neurodegenerative (eye)
phenotype,16,19 even though there has not, as yet, been any
demonstration of the functional significance of Pur a in rescuing a
CGG-repeat-induced neurodegenerative phenotype in a mammalian
system.
More recently, Muslimov et al.20 presented evidence based on rat
neuronal transfection experiments, that binding of hnRNP A2 to the
expanded CGG-repeat RNA interferes with its binding to the non-
coding RNA, BC1, which normally facilitates dendritic transport of
mRNAs that are required for synaptic function. In addition, they
showed that overexpression of hnRNP A2 partially reversed the
impaired dendritic transport of an mRNA known to be targeted for
dendritic transport. These intriguing observations point to a possible
role for hnRNP A2 in the pathogenesis of FXTAS. However, many
dendritically-transported mRNAs occur via mechanisms that are likely
to be independent of BC1.21 Thus, to assess what role, if any, that
hnRNA A2 and/or BC1 play in FXTAS, it will be essential to study
their roles in vivo, e.g., with knock-in (KI) mice.
Finally, Sellier et al.22 reported preliminary findings that the
expanded CGG-repeat RNA sequesters DiGeorge syndrome critical
region 8 (DGCR8) protein (haploinsufficient in DiGeorge syndrome/
22qdel syndrome).23,24 DGCR8, along with the RNase III Drosha,
constitutes the microRNA (miR) nuclear processing complex that
cleaves primary miRNAs (pri-miRs residing within portions of larger
RNA transcripts) into precursor miRNAs (pre-miRs) in the miR
biogenesis pathway.25 The importance of the observation by Sellier et
al.22 is that substantial miR dysregulation (low miRs and elevated
levels of pri-miRs) is observed in the brains of FXTAS cases.
Although one or more of these proteins, when sequestered, may
mediate the ‘‘toxicity’’ of the FMR1 mRNA, there is still little
understanding as to the downstream consequences of their actions.
The problem is particularly daunting for both the DGCR8 protein,
where reductions of multiple miRs would be expected to influence the
expression of hundreds of proteins and many pathways, and for
hnRNP A2, which is likely to facilitate the transport of many mRNAs
of diverse function. Thus, even though we know of specific aspects of
cellular dysfunction, e.g., mitochondrial abnormalities,26,27 altered
lamin A nuclear architecture,28 and reduced telomere length,29 we do
not know how they are linked. The challenge is now to ‘‘connect the
dots’’ between the basic sequestration mechanism and the downstream
processes that lead to disease.
The broader implications of FXTAS to
neurodegenerative disease
The spectrum of clinical involvement among individuals with
FXTAS includes features of both parkinsonism30–32 and dementia,33,34
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suggesting that studying the pathogenesis of FXTAS might shed light
on the pathogenesis of both PD and AD, since there are likely to be
shared mechanisms of neurodegeneration among the three disorders.
Indeed, for idiopathic PD, there is growing evidence of a pathogenic
synergism at the level of mitochondrial dysfunction. The involvement
of mitochondrial dysfunction in both PD and AD is well-known.35–38
However, evidence of mitochondrial dysfunction has only recently
become apparent for FXTAS, and more broadly among carriers of
premutation FMR1 alleles.26,27,31,32
Since both FXTAS and PD are associated with altered mitochon-
drial function, this suggests that premutation alleles can contribute in
two ways to the clinical burden of PD, and more broadly,
parkinsonism, in society. Firstly, since parkinsonism is an associated
feature of FXTAS, premutation alleles of the FMR1 gene would
directly contribute to cases of parkinsonism, or the misdiagnosis of
PD.2 Both mechanistically and clinically, such cases are distinct from
PD and are therefore likely to respond poorly to therapeutic
approaches for treating PD. However, given the much higher
frequency of PD and atypical parkinsonism compared to premutation
carrier frequency in the general population, misdiagnosis of FXTAS as
PD would be of note as a failure to detect the former, and, therefore,
carriers of premutation alleles.
Secondly, and perhaps more importantly, both gray zone (,45–54
CGG repeats) and premutation alleles may contribute directly to the
appearance and/or severity of PD,31 albeit by entirely separate
mechanisms, if such mechanisms affect common features of neuronal
viability, e.g., mitochondrial function.39 Such a confluence leads to the
prediction that both the genetic and environmental factors that
contribute to late-onset PD may contribute to the penetrance and
severity of some cases of FXTAS, perhaps influencing why some
premutation carriers develop FXTAS, where others, with an identical
number of CGG repeats, do not develop this neurodegenerative
disorder. Thus, as a general principle of disease pathogenesis, the
example of a possible interplay between the premutation and PD, e.g.,
Figure 1. Overview of the Expression of the FMR1 Gene. FMR1 mRNA levels increase with increasing CGG-repeat length (gold segments) throughout the
premutation range, and undergo a transition to greatly diminished levels in the full mutation range because of hypermethylation of the FMR1 promoter region. In some
instances, methylation mosaicism results in continued production of low-to-moderate levels of mRNA in the full mutation range. RNA toxicity in the premutation range
is thought to arise through sequestration, by direct binding to the expanded CGG-repeat element within the FMR1 mRNA, of one or more RNA binding proteins that
would normally be associated with other mRNAs. Sequestration in turn leads to loss of the normal function(s) of those proteins, which may include splice modulation and
regulation of miRNA production, among other functions. Dysregulation of RNA processing is thought to lead to multiple forms of downstream cellular dysregulation.
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mitochondrial dysfunction, oxidative stress, etc., could also extend to
the mitochondrial dysfunction in AD, to idiopathic autism26 and to
other disorders that share both phenotypic domains and overlapping
or convergent mechanisms.
Going back in time
One of the remarkable and unexpected outcomes of research on
FXTAS, particularly from mouse studies, is finding that the
premutation allele leads to early developmental abnormalities that
are evident even in late embryonic development. In particular,
embryonic premutation mice have both abnormal neuronal migration
in the neocortex and altered neuronal differentiation.40 Furthermore,
cultured hippocampal neurons from neonatal mice bearing premuta-
tion FMR1 alleles develop shorter and fewer dendritic branches than
wildtype (WT) littermates,41 and although, the numbers of synaptic
puncta do not differ between the premutation and WT mice, the
premutation puncta are larger.
The premutation mice also manifest neurodevelopmental beha-
vioral/cognitive deficits that probably reflect a much broader (and
earlier) spectrum of involvement among premutation carriers than the
late-adult-onset neurodegenerative disorder, FXTAS. Hunsaker et
al.42 demonstrated that at 12 and 24 weeks of age, premutation mice
did not recognize changes in the distance between two objects (metric
task), but were able to detect transposition of the objects (topological
task). However, at 48 weeks, this second ability was also lost. The
authors’ results suggest that altered hippocampal-dependent spatial
processing may precede the impaired parietal cortex function
associated with FXTAS. In addition, parallel studies in human
premutation carriers (females aged 21 – 42 years), Goodrich-Hunsaker
et al.43 observed modulated cognitive impairments using a quantitative
magnitude comparison task—consistent with the results of the mouse
studies—suggesting a neurocognitive phenotype associated with some
premutation carriers that appear much earlier than the motor/
cognitive impairments associated with FXTAS.
Similar conclusions were obtained from the study of a second KI
mouse model44,45 that extended the studies of dendritic morphology in
cultured hippocampal neurons.41 Although both the in vitro and in vivo
studies revealed consistent decreases in complexity of dendritic
branching, Qin et al.44 observed increased spine density, in apparent
contrast to the absence of any difference in density between WT and
KI cultured neurons.41 This distinction is important; since Qin et al.44
posited that the spines in their KI mice were immature, perhaps
signaling a defect in synaptic plasticity. These authors proposed further
that their observations could be explained by dramatically decreased
FMRP levels in their mice. However, the mouse model used by Chen
et al.41 shows only a ,40% decrease in FMRP level for the same
CGG-repeat range, ,100–150 CGG repeats,46 which is comparable
to the relative FMRP levels observed in human blood lymphocytes.47–49
This decrease is nowhere near the dramatic reductions observed by Qin
et al.44 Therefore, whereas reduction in FMRP may play a significant
role in the Qin et al. mouse model, it is likely to play a lesser role in the
Chen et al. study. The question remains as to how two very similar
mouse models of the same background strain and nearly identical KI
sequences can have such differences in FMRP expression. Resolution of
this issue has clinical implications, since for many of the children with
premutation alleles who have neurodevelopmental problems (e.g.,
autism, ASD, ID and ADHD), mild reductions in FMRP levels may yet
be playing a role. Clearly, the involvement of FMRP in premutation-
associated disorders needs further investigation.
Collectively, the mouse and human studies imply that there is a
broad spectrum of clinical and cellular developmental involvement
among carriers of premutation alleles, which is evident both at an early
age and, most likely, in a broader cross-section of carriers than those
who will eventually develop FXTAS. On the one hand, these
observations provide an important foundation for understanding the
known neurodevelopmental/behavioral problems suffered by some
children who are carriers of a premutation allele.47,48,50–52 On the
other hand, such observations also present a challenge for interpreting
mouse and human neurodevelopmental studies—namely, to what
extent any of the cellular and clinical findings are predictive of late-
onset neurodegeneration. Thus, premutation allele status does not
imply that one will necessarily develop FXTAS or associated
neurocognitive decline, yet in some manner that we do not fully
understand, a premutation allele increases the risk of the late-onset
disorder. Indeed, the whole issue of incomplete penetrance is a major
challenge to our understanding of FXTAS. In this regard, there is a
need for informative biomarkers that will help predict who will develop
FXTAS and how such individuals will respond to therapeutic
intervention.
FXTAS versus premutation-associated disease
The uncertain relationship between FXTAS and premutation status
reprises the whole issue of how one assigns a particular form of clinical
involvement among premutation carriers to the canonical disorder of
FXTAS, a forme fruste of the disorder, or a mechanistically distinct
feature of the premutation that is not prodromal to, or co-morbid with,
the disorder. Whereas it is evident that the list of co-morbid conditions
with FXTAS is growing (e.g., fibromyalgia;8,9,53 autoimmune thyroid
disease;8 psychopathology, including depression and anxiety disor-
ders;54 and, sleep apnea55), the relationship(s) between the manifesta-
tion of cognitive and behavioral impairment in childhood, FXPOI in
young adults,56,57 mood-instability and psychiatric conditions, and
late-onset neurodegeneration remain obscure except that they are
probably all related to RNA toxicity. However, the recent finding that
both lowered FMRP and elevated mRNA are correlated with
amygdala dysfunction in young adult males with the premutation49
suggests that additional gene dysfunction at the level of lowered
FMRP, particularly for large CGG-repeat alleles, may be additive to
the effect of the RNA toxicity. Thus, additional studies of the role(s)
played by both RNA and protein may help to differentiate the various
forms of premutation involvement.
The broad challenge of defining the relationship between premuta-
tion status and disease formation will only be met through the
identification of the common and divergent mechanisms that underlie
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the family of premutation disorders. Indeed, although FXTAS is
principally a premutation disorder, the RNA-toxicity mechanism
predicts that occasional individuals with alleles producing excess FMR1
mRNA that are outside of the premutation range may, nevertheless,
manifest some characteristics of FXTAS. Consistent with this
prediction, Hall et al.58 reported a case of an older adult male with
fragile X syndrome who developed a progressive neurodegenerative
syndrome. This individual was mosaic for allele size, with approxi-
mately 80% full mutation alleles and the remaining 20% consisting of
a small premutation allele (,70 CGG repeats). This case is interesting
in its ambiguity; a preponderance of full mutation alleles giving rise to
fragile X syndrome, but a minority of premutation alleles that could be
responsible for his late neurodegenerative course. Less ambiguous is
the report of a male with clinical and radiological features (middle
cerebellar peduncle sign) of FXTAS, but who was a carrier of an
unmethylated, full mutation allele.31 The recent observation of (rare)
intranuclear inclusions in three older adult males with methylated, or
methylation-mosaic full mutation alleles, and fragile X syndrome,59
suggests that residual RNA expression from full mutation alleles can
lead to neuropathologic features normally associated with FXTAS;
but, in these three cases, typical clinical features of FXTAS were not
evident. However, parkinsonism is common in aging patients with
fragile X syndrome60 with no difference between those with a full
mutation and those with (pre/full mutation) mosaicism. Therefore the
aging problems in fragile X syndrome are unlikely to be related to
RNA toxicity; diminished adult neurogenesis is one possibility.61
FMR1 alleles with gray-zone expansions (i.e., between the normal
and premutation ranges) may also lead to features of FXTAS in some
cases,31,32,62 particularly if the FMR1 mRNA levels are elevated within
that range.63 Interestingly, the rate of FXPOI is also elevated in the
gray zone,56,57 again pointing to a shared mechanism. These cases,
lying outside of the premutation range, underscore the possibility of
additional genetic and/or environmental modifiers, perhaps the same
factors that determine penetrance within the premutation range.
However, it should be noted that the majority of studies have not
found increased premutation or gray zone alleles in patients with
parkinsonism.64–70 Thus, there remains a fundamental uncertainty
with respect to the involvement of gray-zone alleles in the
neurodegenerative phenotypes (e.g., FXTAS, PD) that will require
either much larger studies or a clear mechanistic understanding of how
such alleles might contribute to disease pathogenesis.
Concluding remarks
FXTAS is an important neurodegenerative disorder, not only from
the standpoint of its clinical severity, but also because of what it can tell
us about shared mechanisms across the spectrum of late-onset
identification of mechanistic associations with various domains of
clinical involvement (e.g., reproductive failure, cognitive impairment)
that are far removed from its core neurologic features of tremor and
ataxia. The elucidation of these shared mechanisms (e.g., mitochon-
drial dysfunction39) should lead to improved disease biomarkers and
novel therapeutic approaches, not only for the more common
neurodegenerative disorders (PD, AD), but also for mechanistically
linked neurodevelopmental involvement.
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